NORGINE LAUNCHES MOVICOL READY TO TAKE TRINKFERTIG IN GERMANY

Back to media releases
Next media release
20 June 2016

 

 

NORGINE LAUNCHES MOVICOL® READY TO TAKE (TRINKFERTIG) IN GERMANY
 

Building on the trusted reputation of MOVICOL® over the last 20 years.
 

Demonstrating Norgine’s expertise in gastroenterology with the development and commercialisation of innovative products.

 

LONDON, UK, Monday 20 June, 07:00 BST. Norgine B.V. today announced the launch of MOVICOL® Ready to Take in Germany. In Germany it is called MOVICOL® trinkfertig. MOVICOL®  Ready to Take is used for the treatment of acute and chronic constipation in adults, adolescents and the elderly.[1]
 

MOVICOL® Ready to Take is a ready mixed, pocket size dose that can be taken anywhere, at any time. It is an extension to the product line of the well-established MOVICOL® brand which has been available for over 20 years in Europe and Australia/New Zealand via Norgine’s infrastructure and in the rest of world through a network of partners.
 

Peter Martin, COO at Norgine said: “The launch of MOVICOL® Ready to Take in Germany reinforces Norgine’s ability to develop and commercialise products that offer value to healthcare professionals, health systems and more importantly that meet patients’ needs.”
 

He added: “The first launch of the new MOVICOL® Ready to Take is significant for Norgine, as it builds on MOVICOL®’s leading position, but it also continues to demonstrate Norgine’s gastroenterology expertise and capabilities as a European specialist pharma company.”
 

Norgine anticipates launching MOVICOL® Ready to Take through its European infrastructure later on this year.
 

 

Ends

Notes to Editors:
 

About MOVICOL Ready to Take (trinkfertig) in Germany

Go to www.movicol.de
 

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
 

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
 

For more information, please visit www.norgine.com
 

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
 

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

 

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine

 

GL/MOV/0616/0063
June 2016

 

References


[1] MOVICOL Ready To Take. Instructions For Use. September 2015.